TAO: Otamixaban Disappoints in NSTE-ACS TAO: Otamixaban Disappoints in NSTE-ACS

The new IV factor Xa inhibitor was not superior to heparin plus eptifibatide in reducing death/MI but did increase bleeding among patients with NSTE-ACS and a planned invasive strategy. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news